Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Phase of Trial: Phase IV
Latest Information Update: 12 Apr 2016
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Epilepsy
- Focus Pharmacodynamics
- Sponsors Sunovion Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 01 Apr 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Feb 2016 Planned end date changed from 1 Jan 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.